Trodelvy® significantly reduces the risk of disease progression or death by 38% in metastatic triple- negative breast cancer patients compared to traditional chemotherapy. The stock price of Gilead Sciences has seen a 4.21% increase, reaching a high of $124.11, which is its highest over the past year. Gilead Sciences maintains a strong market position with a market capitalization of approximately$152.38 billion and active investor interest. Gilead Sciences has a substantial market capitalization of approxi ...